Said Dr. Sheela Vijay, President of VLNB, “We’re delighted to open this facility that promises to accelerate our commercial development of novel immunotherapy. This Company has been a lifelong dream for our Chief Scientific Officer, Dr. Hari Vijay, who founded VLNB after a distinguished research career at Health Canada studying pollen and mold allergies”.
The American College of Occupational and Environmental Medicine (http://www.acoem.org/)
VLNB seeks to partner with companies and research organizations to accelerate commercial development of immunotherapy to treat mold allergies. VLNB also offers customized consulting services led by Dr. Hari Vijay.
About VLN Biotechnology
VLN Biotechnology is commercializing immunotherapy technology to improve the health and quality of life of patients suffering from allergies to mold. We are focused on improved detection of allergenic proteins responsible for allergic reactions and development of immunotherapy to alleviate symptoms of mold allergies. VLN Biotechnology was founded by Dr. Hari Vijay, an acknowledged global expert on mold allergens. For further information please visit www.vln-biotech.com.